FAIM
VKTX icon

Financial Advocates Investment Management’s Viking Therapeutics VKTX Stock Holding History

Financial Advocates Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,500
Closed -$837K – 840
2021
Q1 		$837K Buy
+16,500
New +$116K 0.06% 362

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Financial Advocates Investment Management's VKTX Position: Q2 2021 in Review

Financial Advocates Investment Management sold out of Viking Therapeutics (VKTX) in Q2 2021, closing a stake of 16,500 shares — an estimated $837K sold.

Financial Advocates Investment Management first reported a position in VKTX in Q1 2021 and held it in 1 quarter. The position peaked at $837K in Q1 2021. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2021.

  • Financial Advocates Investment Management reported no remaining Viking Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Financial Advocates Investment Management sold 16,500 Viking Therapeutics shares in Q2 2021, an estimated $837K.
  • Financial Advocates Investment Management first reported a position in Viking Therapeutics in Q1 2021 and held it in 1 quarter.
  • Financial Advocates Investment Management's Viking Therapeutics position peaked at $837K in Q1 2021.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2021.

Based on Financial Advocates Investment Management's 13F filing for Q2 2021, filed 3 Aug 2021.